Raymond James Initiates LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $37
Piper Sandler Maintains Overweight on LENZ Therapeutics, Maintains $36 Price Target
BofA Securities Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $31
Piper Sandler Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $36
LENZ Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target
H.C. Wainwright Maintains LENZ Therapeutics(LENZ.US) With Buy Rating, Maintains Target Price $38
BofA Securities Initiates LENZ Therapeutics(LENZ.US) With Buy Rating, Announces Target Price $31
LENZ Therapeutics Price Target Announced at $38.00/Share by HC Wainwright & Co.
LENZ Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intuitive Surgical (ISRG) and Silence Therapeutics (SLN)
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $9 Price Target
Sarepta Therapeutics Inc: Royal Bank of Canada cuts industry performance from outperforming the market; cuts target price from $157 to $142
Analysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Tango Therapeutics (TNGX)
Tango Therapeutics, Inc.: H.C. Wainwright cuts target price from $16 to $13
CytomX Therapeutics Analyst Ratings
Piper Sandler Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $3.5
Kepler Capital Remains a Buy on Calliditas Therapeutics (CALT)
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
Truist Financial Issues a Buy Rating on Kymera Therapeutics (KYMR)
No Data
No Data